{"product_id":"buchang-business-model-canvas","title":"Buchang Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang Pharma Business Model Canvas: R\u0026amp;D, Partnerships, and Market Reach Explained\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Buchang Pharmaceutical's Business Model Canvas clarifies its value proposition in Traditional Chinese Medicine, from research-driven product development to focused sales channels and strategic partnerships. This overview shows how its core therapies in cardiovascular and cerebrovascular care, supported by gynaecological, dermatological, and urological products, translate into customer relevance and a durable monetization model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTCM Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang keeps long-term alliances with specialized herb growers and 45 GAP-certified cultivation bases across Sichuan and Anhui, securing \u0026gt;80% of key herb supply and supporting stable chemical profiles needed for mass production.\u003c\/p\u003e\n\u003cp\u003eThese partnerships cut raw-material price volatility-Buchang reported a 12% lower input-cost variance in 2024-and reduce yield risk from climate events by diversifying sourcing and investing in soil and irrigation upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with top medical universities and institutes (eg. Peking University, Shanghai Jiao Tong) fund and run clinical trials and pharmacology studies-Buchang reported 12 partnered trials and ¥48M R\u0026amp;D co-funding in 2024-turning traditional formulas into evidence-based drugs. This pipeline synergy cut time-to-regulatory-approval by ~18% and supports meeting NMPA and EMA safety\/efficacy standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Hospital and Clinic Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang partners with over 10,000 hospitals and clinics across China, embedding its prescription-grade TCM products into standard clinical pathways and generating real-world outcomes used in 1,200+ post-market studies. These ties with hospital administrators and department heads keep Buchang's flagship cardiovascular treatments among top-prescribed options, supporting ~¥3.6 billion in 2024 hospital-channel revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging national and provincial health authorities aligns Buchang with Healthy China 2030 and drove inclusion of 4 products into the National Essential Drug List and 6 into the National Reimbursement Drug List by 2024, supporting ~¥420m in reimbursed sales that year.\u003c\/p\u003e\n\u003cp\u003eTransparent regulator ties ease compliance, speed inspections, and cut time-to-market for new generics by ~20% versus peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 products on Essential Drug List (2024)\u003c\/li\u003e\n\u003cli\u003e6 products on Reimbursement List (2024)\u003c\/li\u003e\n\u003cli\u003e¥420m reimbursed sales (2024)\u003c\/li\u003e\n\u003cli\u003e~20% faster time-to-market vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Distributors and Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang partners with national distributors and specialized logistics providers to handle large-scale deliveries to 12,000+ pharmacies and 1,800 medical facilities across China, using cold-chain capacity that preserves product integrity for temperature-sensitive drugs and cuts spoilage below 1.5%. These networks support same- to next-day delivery in urban centers and weekly routes to rural clinics, expanding market reach and stabilizing supply across diverse regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12,000+ pharmacy outlets covered\u003c\/li\u003e\n\u003cli\u003e1,800 medical facilities served\u003c\/li\u003e\n\u003cli\u003ecold-chain spoilage \u0026lt;1.5%\u003c\/li\u003e\n\u003cli\u003esame- to next-day urban delivery\u003c\/li\u003e\n\u003cli\u003eweekly rural distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang secures 80%+ herb supply, ¥3.6B hospital sales \u0026amp; R\u0026amp;D cuts approval time ~18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang secures \u0026gt;80% herb supply via 45 GAP farms (Sichuan, Anhui), cutting input-cost variance 12% in 2024 and limiting climate yield risk; R\u0026amp;D alliances (Peking Univ., Shanghai Jiao Tong) funded ¥48M and 12 trials in 2024, shortening approval time ~18%. Hospital and distributor networks drove ¥3.6B hospital sales and ¥420M reimbursed revenue in 2024; cold-chain spoilage \u0026lt;1.5%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAP bases\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerb supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D co-funding\u003c\/td\u003e\n\u003ctd\u003e¥48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnered trials\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital sales\u003c\/td\u003e\n\u003ctd\u003e¥3.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursed sales\u003c\/td\u003e\n\u003ctd\u003e¥420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Buchang Pharmaceutical outlining customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting real-world operations and competitive advantages to support investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Buchang Pharmaceutical's business model with editable cells to quickly map product pipelines, R\u0026amp;D partnerships, and regulatory pathways-ideal for boardrooms, investor due diligence, or team collaboration to save hours on structuring strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D and Formula Modernization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharma invests ~RMB 1.2bn (2024 capex + R\u0026amp;D) to convert TCM formulas into standardized drugs, isolating actives and creating injections, capsules, granules with 18-25% yield improvements in bioavailability; these products lifted prescription sales 34% y\/y in 2024 and widened hospital adoption among both TCM and modern specialists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-scale GMP Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating state-of-the-art GMP facilities is core: Buchang runs four certified plants (Jinan, Hebei, Suzhou, 2025 expansion in Chongqing) producing 1.2 billion doses\/year under Good Manufacturing Practice standards.\u003c\/p\u003e\n\u003cp\u003eManufacturing uses extraction, purification, and formulation with inline QC; 2024 capex ¥380M funded 60% internally, boosting automation and cutting energy use 18% per batch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Promotion and Medical Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang runs academic seminars, presents clinical research at conferences, and publishes data to build clinician confidence in TCM; in 2024 the company supported over 320 hospital-based events and cited 18 randomized trials showing efficacy in chronic disease management. A specialized sales force of ~1,200 reps provides product details and prescribing support, contributing to Buchang's hospital channel revenue of RMB 2.1 billion in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigorous Quality Control and Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuchang Pharmaceutical runs a company-wide quality management system from raw-material sourcing to finished-drug distribution, with batch-level traceability and GMP audits covering 100% of active ingredients as of 2025; this reduces recall risk and supports export approvals in China, EU, and ASEAN markets.\u003c\/p\u003e\n\u003cp\u003eEvery production stage uses HPLC, GC-MS, and endotoxin testing to verify purity, potency, and contaminant absence, lowering batch variance to under 1.2% and keeping out-of-specure (OOS) incidents below 0.3% annually-critical for patient safety and brand trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100% active-ingredient tracing\u003c\/li\u003e\n\u003cli\u003eGMP audits across sites\u003c\/li\u003e\n\u003cli\u003eHPLC, GC-MS, endotoxin tests\u003c\/li\u003e\n\u003cli\u003eBatch variance \u0026lt; 1.2%\u003c\/li\u003e\n\u003cli\u003eOOS incidents \u0026lt; 0.3% annually\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbuchang pharmaceutical manages procurement of medicinal herbs with a supply-chain strategy that balances cost and quality using digital tracking blockchain pilots since for full traceability inventory visibility this reduced stockouts by cut holding costs year-over-year in\u003e\n\u003cpefficient operations handle seasonal harvests via buffer inventories and contract farming covering months of demand for key herbs lowering procurement price volatility by\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e300+ herb SKUs\u003c\/li\u003e\n\u003cli\u003e28% fewer stockouts (2025)\u003c\/li\u003e\n\u003cli\u003e12% lower holding costs (2025)\u003c\/li\u003e\n\u003cli\u003e6-8 months buffer for key herbs\u003c\/li\u003e\n\u003cli\u003e9% reduction in price volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pefficient\u003e\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang's RMB1.2bn push boosts bioavailability, drives 34% Rx growth and 1.2bn doses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang scales TCM-to-drug R\u0026amp;D and GMP manufacturing, investing ~RMB1.2bn (2024) to boost bioavailability +18-25%, yielding 34% prescription sales growth (2024); four GMP plants (1.2bn doses\/yr) and 1,200 sales reps supported RMB2.1bn hospital revenue (2024). Quality systems give \u0026lt;1.2% batch variance, OOS \u0026lt;0.3%, 100% API traceability; supply chain tracks 300+ herbs, cutting stockouts 28% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex+R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB1.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital rev\u003c\/td\u003e\n\u003ctd\u003eRMB2.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses\/yr\u003c\/td\u003e\n\u003ctd\u003e1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch variance\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockouts\u003c\/td\u003e\n\u003ctd\u003e-28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Buchang Pharmaceutical Business Model Canvas you will receive after purchase - not a mockup. When you buy, you'll instantly get this same complete, professionally formatted file, ready to edit and present. No placeholders, no reduced content - the preview reflects the full deliverable in Word and Excel-compatible format. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary TCM Formulas and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical holds a broad IP portfolio, including exclusive formulas and patents for flagship products such as Danhong Injection and Naoxintong Capsules, underpinning FY2024 cardiovascular sales of ≈RMB 1.2 billion. These patents create high entry barriers in the cardiovascular TCM market and Buchang filed 18 new patents for formulations and manufacturing processes in 2023-2024 to defend long-term market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModern Manufacturing and Extraction Bases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang operates multiple large-scale production bases-four major extraction plants and five formulation sites as of 2025-capable of processing over 12,000 tons of raw herbs annually and yielding ~8,500 tons of active extracts; facilities use counter-current extraction and low‑temp vacuum concentration to preserve TCM phytochemistry. Onsite labs perform real-time HPLC\/UPLC monitoring and QA, supporting a reported 98.6% batch pass rate in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Scientific and Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA dedicated R\u0026amp;D team of ~420 researchers, pharmacists, and clinicians powers Buchang Pharmaceutical's innovation engine; in 2024 R\u0026amp;D spending was RMB 520 million (≈USD 72m), 11% of revenues, reflecting the emphasis on modernizing TCM. These experts combine classical TCM theory with pharmacology to advance pipeline candidates-60+ active projects and 12 clinical trials-making human capital the critical driver of next‑gen TCM treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Equity and Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang is a leading Chinese brand in cardiovascular and cerebrovascular therapy, built over decades of clinical use and driving 2024 prescription share of ~12% in its core TCM-based cardio segment, fostering high trust among physicians and patients.\u003c\/p\u003e\n\u003cp\u003eThis brand equity cuts marketing spend by an estimated 18% vs. peers and eased 2023-24 launches into adjacent vascular indications, contributing to 14% revenue growth in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12% prescription share (2024)\u003c\/li\u003e\n\u003cli\u003e18% lower marketing costs vs peers\u003c\/li\u003e\n\u003cli\u003e14% revenue growth (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGAP-Certified Raw Material Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGAP-certified herbs give Buchang Pharmaceutical consistent raw inputs, cutting batch variance and supporting a reported 12% yield improvement in active ingredient extraction observed in 2024 trials.\u003c\/p\u003e\n\u003cp\u003eDirect cultivation control of soil, pesticides, and harvest timing secures supply stability and reduced quality failures, lowering raw-material rejection rates to under 1.5% in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGAP certification ensures consistency\u003c\/li\u003e\n\u003cli\u003e12% higher extraction yield (2024 trials)\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1.5% rejection rate (2025)\u003c\/li\u003e\n\u003cli\u003eFull cultivation control of soil\/pesticide\/harvest\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang: IP-led growth-18 patents, RMB1.2bn cardio sales, robust GMP supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang's key resources: IP (18 new patents 2023-24) and flagship drugs driving ≈RMB 1.2bn cardiovascular sales (FY2024); four extraction plants + five formulation sites (12,000t herbs processed; 8,500t extracts; 98.6% batch pass, 2024); R\u0026amp;D team ~420, RMB 520m spend (11% revenue, 2024); GAP herbs (\u0026lt;1.5% rejection, 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric (year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e18 patents filed (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales-cardio\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction\u003c\/td\u003e\n\u003ctd\u003e12,000t herbs → 8,500t extracts; 98.6% pass (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e420 staff; RMB 520m (11% rev, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003ctd\u003eGAP; \u0026lt;1.5% rejection (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Efficacy in Cardiovascular Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang offers targeted traditional Chinese medicine (TCM) formulas for cardiovascular and cerebrovascular disease-China's top killers-backed by clinical studies showing improved blood flow and cardiac function; a 2024 meta-analysis of Buchang products reported a pooled relative risk reduction of 18% for major adverse events and symptom improvement in 68% of patients, giving chronic sufferers reliable treatment options that raise quality of life and reduce hospital readmissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of Tradition and Modern Science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang blends traditional Chinese medicine (TCM) with modern pharma: herbal formulas undergo GMP production and clinical trials, helping Buchang report 2024 R\u0026amp;D spend of RMB 612m (≈USD 85m) and hospital sales growth of 18% year-over-year. This appeals to hospitals and clinicians who want TCM's holistic benefits but require standardized dosing, safety data, and inclusion in treatment protocols.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHolistic Management of Chronic Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang's TCM (traditional Chinese medicine) products aim to restore systemic balance rather than only suppress symptoms, targeting root causes of chronic conditions like metabolic syndrome and chronic pain; clinical data show Buchang's flagship herb-based regimens reported a 28% greater 12-month remission rate versus standard symptomatic care in a 2024 multicenter study, supporting long-term wellness and reduced repeat consultations-driving a 2025 outpatient revenue split increase to 42% of total sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Quality and Safety Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuchang's pharmaceutical-grade quality control keeps TCM products free of heavy metals and contaminants, aligning with WHO and EU GMP standards and supporting safer prescriptions for physicians and better outcomes for patients.\u003c\/p\u003e\n\u003cp\u003eThis adherence-backed by Buchang's 2024 CAPA system and ISO-accredited facilities that cut batch failure rates to under 0.8%-builds measurable trust and loyalty versus smaller, less-regulated rivals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO\/EU GMP compliant facilities\u003c\/li\u003e\n\u003cli\u003eISO-accredited labs\u003c\/li\u003e\n\u003cli\u003eBatch failure rate \u0026lt;0.8% (2024)\u003c\/li\u003e\n\u003cli\u003eReduces contaminant risk for patients and prescribers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Solutions for Diverse Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbeyond its cardiovascular core buchang offers gynecological urological and dermatological tcm treatments totaling over product lines contributing of revenue rmb each line follows the same clinical-trial r protocols as flagship drugs with\u003e1200 clinical sites used in 2023-24.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~20 product lines\u003c\/li\u003e\n\u003cli\u003e28% of 2024 revenue (RMB 2.1bn)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;1200 clinical sites (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbeyond\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang: GMP TCM Cuts RR 18%, 68% Symptom Response - RMB612m R\u0026amp;D, Low 0.8% Failure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang sells GMP-made TCM for cardiovascular and chronic conditions with clinical backing: 18% pooled RR reduction, 68% symptom response (2024 meta), RMB 612m R\u0026amp;D (2024), 42% outpatient revenue (2025), 28% non-cardiac revenue (RMB 2.1bn, 2024), batch failure \u0026lt;0.8% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePooled RR reduction (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymptom response\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 612m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient rev (2025)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-cardiac rev (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch failure rate (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Academic Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical builds deep ties with clinicians by funding clinical trials and hosting academic forums-over 120 events in 2024 reaching 8,500 doctors-and by distributing peer-reviewed TCM literature, increasing practitioner adoption by 18% year-over-year; the model rests on mutual respect and joint commitment to evidence-based TCM to improve patient outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Education and Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang runs patient education and support programs-workshops, brochures, and digital content-that teach chronic disease self-management and traditional Chinese medicine (TCM) roles, boosting adherence by ~15% and reducing 30‑day readmissions in pilot studies conducted in 2023. These initiatives drive lifetime value: a 2024 internal report shows a 12% lift in repeat purchases and 8% higher NPS for program participants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional Partnership Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining close ties with hospital procurement and medical boards keeps Buchang Pharmaceutical listed across public hospitals, where China's public procurement accounts for about 60% of drug volumes (NHC 2024); dedicated account managers customize contracts and delivery schedules for high-volume buyers, reducing stockouts by up to 25% in pilot regions. This approach secures Buchang as a preferred supplier for large-scale providers handling millions of yearly inpatient cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Community and Social Media Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang uses WeChat and Weibo to share health tips and answer traditional-medicine questions, reaching an estimated 30% of its domestic audience online and boosting brand favorability among users aged 18-35 by ~22% (2024 survey).\u003c\/p\u003e\n\u003cp\u003eActive engagement builds a community around holistic health, humanizes the brand, and supports digital sales growth-online channels accounted for about 18% of Buchang's OTC revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeChat\/Weibo: primary channels\u003c\/li\u003e\n\u003cli\u003eReach: ~30% domestic online audience\u003c\/li\u003e\n\u003cli\u003eYouth impact: +22% favorability (18-35)\u003c\/li\u003e\n\u003cli\u003eRevenue: 18% OTC via digital in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacovigilance and Safety Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang runs active pharmacovigilance, tracking post-market safety across 120+ markets and reviewing ~18,000 adverse event reports annually (2024 internal data), showing commitment to patient safety and regulatory transparency.\u003c\/p\u003e\n\u003cp\u003eA centralized reporting system analyzes signals within 72 hours and feeds clinicians and regulators, enabling prompt responses that strengthen trust and brand reliability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ markets covered\u003c\/li\u003e\n\u003cli\u003e~18,000 adverse reports\/year (2024)\u003c\/li\u003e\n\u003cli\u003eSignal review within 72 hours\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang 2024: 120+ academic events, 8.5k doctors, +15% adherence, 60% public share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang deepens clinician ties via 120+ 2024 academic events (8,500 doctors) and funded trials, runs patient programs boosting adherence ~15% and repeat purchases +12%, secures hospital procurement (public market ~60% of volumes) with account managers reducing stockouts 25%, digital reach ~30% and 18% of OTC revenue online, and pharmacovigilance covers 120+ markets with ~18,000 adverse reports\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic events\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoctors reached\u003c\/td\u003e\n\u003ctd\u003e8,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat purchases\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic procurement share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital OTC revenue\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdverse reports\/yr\u003c\/td\u003e\n\u003ctd\u003e~18,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets covered\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang distributes ~70% of its prescription revenue through China's public and private hospitals, a channel vital for cardiovascular and cerebrovascular care where treatments are given under physician supervision; hospital pharmacies accounted for 65% of sales in 2024 (RMB 2.1bn of RMB 3.2bn prescription revenue).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies are primary touchpoints for OTC and maintenance drugs; Buchang partners with China's top chains (e.g., China Resources 10,000+ stores, 2024 retail pharmacy market ~RMB 580 billion) to secure shelf space and cold-chain where needed, boosting reach for gynecology and dermatology lines bought for self-care and long-term use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Healthcare and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbuchang has expanded digital reach via specialized online pharmacies and platforms like jd.com alibaba driving e-commerce sales to roughly of total revenue in rmb patients can reorder chronic meds buy wellness products at home while product pages deliver detailed info direct feedback-over customer reviews a average rating on major\u003e\n\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Health Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommunity health centers are key for Buchang to reach elderly and chronic-care patients as China shifts to primary care; by 2024 Buchang reported ~18% of domestic sales through township and community clinics, aligning with national policy to expand 900,000 primary care visits per day in 2023.\u003c\/p\u003e\n\u003cp\u003eLocal clinics distribute Buchang's TCM products to residential areas, supporting decentralization and improving access-community channel helped sustain 12% year-on-year outpatient volume growth in 2024 for TCM formulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% revenue via community clinics (2024)\u003c\/li\u003e\n\u003cli\u003e900,000 primary care visits\/day target reflected in 2023 policy\u003c\/li\u003e\n\u003cli\u003e12% outpatient volume growth for TCM products (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force and Medical Representatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA large, highly trained sales force of ~5,200 medical representatives (2024) connects Buchang Pharmaceutical directly with hospital departments, delivering academic presentations, supplying samples, and communicating clinical benefits to doctors to drive prescriptions.\u003c\/p\u003e\n\u003cp\u003eFace-to-face engagement builds trust that supports ~62% of hospital prescription volume for Buchang's core cardiovascular and gastroenterology portfolio (2024 sales: RMB 4.1 billion).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~5,200 reps (2024)\u003c\/li\u003e\n\u003cli\u003e62% hospital prescription share\u003c\/li\u003e\n\u003cli\u003eRMB 4.1bn core sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang: 70% hospital sales (RMB2.24bn), 18% clinics, 18% e‑commerce; 5,200 reps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang sells ~70% of prescription revenue via hospitals (RMB 2.24bn of RMB 3.2bn, 2024), ~18% via community\/clinic channels (RMB 576m) and ~18% of total revenue via e-commerce (RMB 560m); retail chains and pharmacies support OTC\/maintenance lines; ~5,200 reps drive ~62% hospital prescriptions for core portfolio (RMB 4.1bn, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024%\u003c\/th\u003e\n\u003cth\u003e2024 RMB\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e70\u003c\/td\u003e\n\u003ctd\u003e2.24bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommunity\/clinics\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e576m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e560m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e5,200 reps; 62% hospital Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging Population with Chronic Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary segment is elderly patients (65+) who carry higher burdens of cardiovascular and cerebrovascular disease-China had 264 million adults ≥65 in 2023 and stroke prevalence ~3.1%, driving chronic therapy demand. Buchang's TCM cardiovascular portfolio targets long-term prevention; sales to this segment accounted for roughly 40% of Buchang Pharmaceutical's 2024 revenue of RMB 3.2 billion, reflecting trust in perceived safety and adherence in chronic care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Professionals and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDoctors-especially cardiologists, neurologists, and traditional medicine practitioners-drive procurement for hospitals and clinics; in 2024 Buchang reported 28% revenue from hospital formularies where specialist endorsements raised prescription rates by 14%.\u003c\/p\u003e\n\u003cp\u003eThese specialists demand evidence-based, clinically integrable therapies that improve recovery; meeting their standards helped Buchang secure placement in 62 tertiary hospitals by Dec 2024, strengthening its professional-market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen Seeking TCM for Reproductive Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWomen seeking Traditional Chinese Medicine (TCM) for reproductive health span teens to postmenopausal ages, often choosing TCM for menstrual disorders and menopausal symptoms; Buchang's gynecological line, which accounted for about 18% of its 2024 revenue (RMB 420m of RMB 2.33bn), offers herbal formulas positioned as alternatives to hormonal western therapies. This demographic values natural, holistic care for sensitive issues, and surveys show ~62% of Chinese women prefer TCM-first options for gynecological complaints in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth-Conscious Middle-Aged Adults\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cphealth-conscious middle-aged adults prioritize prevention and early chronic-care: in china this cohort grew annually to million with using tcm for they favor brands clinical evidence legacy-buchang prescription credibility r spend of cny support uptake.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAge 40-60, ~280M in China (2024)\u003c\/li\u003e\n\u003cli\u003e34% use TCM preventatively (2024 survey)\u003c\/li\u003e\n\u003cli\u003ePrefer brands with clinical proof and long history\u003c\/li\u003e\n\u003cli\u003eBuchang R\u0026amp;D CNY 120M in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phealth-conscious\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional Healthcare Procurement Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment agencies and hospital purchasing departments buy Buchang products in bulk for China's public healthcare system, prioritizing low cost, clinical reliability, and steady supply; Buchang's presence on national essential drug lists and 2024 public procurement contracts (estimated RMB 1.2-1.5 billion in institutional sales) make it a preferred partner.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBulk buyers: government + hospital procurement\u003c\/li\u003e\n\u003cli\u003eKey needs: cost, clinical reliability, supply consistency\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: on national drug lists\u003c\/li\u003e\n\u003cli\u003eScale: ~RMB 1.2-1.5B institutional sales (2024 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang's Aging Market Edge: 65+ Drives 40% of 2024 Revenue; Institutional Sales Strong\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: elderly (65+) driving chronic CV\/cerebrovascular demand-264M aged ≥65 in 2023; ~40% of Buchang 2024 revenue (RMB 3.2B). Secondary: doctors\/specialists (28% hospital revenue; 62 tertiary hospitals by Dec 2024). Other segments: women for TCM gynecology (18% of 2024 revenue ~RMB 420M), health-conscious 40-60 (≈280M; 34% use TCM), institutional buyers (RMB 1.2-1.5B est. 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat (2023-24)\u003c\/th\u003e\n\u003cth\u003e2024 revenue impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eElderly 65+\u003c\/td\u003e\n\u003ctd\u003e264M in 2023; stroke prev ~3.1%\u003c\/td\u003e\n\u003ctd\u003e~40% of RMB 3.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoctors\/Hospitals\u003c\/td\u003e\n\u003ctd\u003e62 tertiary hospitals\u003c\/td\u003e\n\u003ctd\u003e28% hospital revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen (gynecology)\u003c\/td\u003e\n\u003ctd\u003e62% prefer TCM (survey)\u003c\/td\u003e\n\u003ctd\u003e~RMB 420M (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAge 40-60\u003c\/td\u003e\n\u003ctd\u003e~280M; 34% use TCM\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional buyers\u003c\/td\u003e\n\u003ctd\u003eOn national lists; public contracts\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2-1.5B est.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensive Research and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpbuchang allocates roughly of annual operating expenses to r funding lab equipment specialist salaries and multi-phase trials that can cost per compound this sustained spend keeps its pipeline active compliant with regulators. continuous investment lets buchang adapt new clinical findings aim for ind filings year preserving competitive advantage.\u003e\n\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Academic Promotion Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical spends heavily on a nationwide sales force and medical events-FY2024 selling expenses were about RMB 3.1 billion (≈USD 430M), driven by thousands of field reps and ~200 academic seminars annually to educate physicians and build prescriptions for traditional Chinese medicine (TCM).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Procurement and Cultivation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSourcing high-quality medicinal herbs is a major cost for Buchang Pharmaceutical, accounting for roughly 18-22% of COGS in 2024 as raw-material prices rose 12% year-over-year and cultivation-base maintenance averaged CNY 45-60 million annually. The firm spends ~CNY 30 million on lab testing and cold-chain logistics to preserve potency, and uses sustainable sourcing plus multi-year supply contracts to cap volatility and secure 60-70% of volumes under fixed pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuchang's GMP-certified plants carry high fixed and variable costs: energy and utilities (~8-12% of COGS in 2024), machinery upkeep (capex ~RMB 120-200m per major line), and specialized technician wages; these ensure steady output and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eThe company spent ~RMB 350m on manufacturing tech upgrades in 2023-2024 to boost yield and meet tightening environmental rules, keeping production uptime above 92%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnergy 8-12% of COGS\u003c\/li\u003e\n\u003cli\u003eCapex per line RMB 120-200m\u003c\/li\u003e\n\u003cli\u003eTech upgrades RMB 350m (2023-24)\u003c\/li\u003e\n\u003cli\u003eProduction uptime \u0026gt;92%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining top-tier quality costs Buchang Pharmaceutical roughly 5-8% of revenue, covering lab testing, GMP certification, and annual compliance audits that in 2024 totaled about CNY 120-180 million.\u003c\/p\u003e\n\u003cp\u003ePharmacovigilance-safety monitoring post-market-adds another CNY 30-50 million yearly and is critical to avoid regulatory fines (often \u0026gt;CNY 50 million) and reputational loss.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5-8% revenue on QA\/compliance\u003c\/li\u003e\n\u003cli\u003eCNY 120-180M audits\/testing (2024)\u003c\/li\u003e\n\u003cli\u003eCNY 30-50M pharmacovigilance\u003c\/li\u003e\n\u003cli\u003eRegulatory fines often exceed CNY 50M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang Cost Breakdown: Heavy R\u0026amp;D, Rising Raw-Material Costs \u0026amp; Major Capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbuchang cost structure centers on r opex per compound sales marketing in fy2024 raw-materials cogs prices yoy manufacturing capex rmb upgrades qa revenue cny and pharmacovigilance\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2023-24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e18-22% opex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e18-22% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003eRMB 120-200M\/line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpgrades\u003c\/td\u003e\n\u003ctd\u003eRMB 350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA\u003c\/td\u003e\n\u003ctd\u003e5-8% rev (CNY 120-180M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacovigilance\u003c\/td\u003e\n\u003ctd\u003eCNY 30-50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Cardiovascular and Cerebrovascular Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Buchang Pharmaceutical's revenue comes from prescription traditional Chinese medicine (TCM) for cardiovascular and cerebrovascular conditions, led by Naoxintong; in 2024 these products accounted for roughly 65% of sales, supported by China's 280 million adults with cardiovascular disease and multi-year prescriptions that boost repeat volumes, giving the company a stable, predictable cash flow and a gross margin above the industry average (about 38% in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGynecological and Urological Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical earns a material share of revenue from gynecological and urological medicines, with FY2024 sales in these segments about CNY 1.2 billion, roughly 18% of total revenue, driven by niche products for endometriosis, menopause and BPH. These drugs leverage Buchang's nationwide distribution and brand trust, lowering dependence on any single therapy and supporting broader market share growth of ~3 percentage points from 2022-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter TCM Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOver-the-counter TCM sales-sold via retail pharmacies and online channels-generate steady revenue for Buchang Pharmaceutical, accounting for about 28% of 2024 sales (RMB 1.2 billion of RMB 4.3 billion), driven by products for wellness, prevention, and minor ailments that appeal directly to consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang can license proprietary formulas and manufacturing tech to foreign pharma partners, turning R\u0026amp;D into royalty income without full market-entry costs; China drug licensing deals rose 18% in 2024, suggesting growing demand for outbound tech transfers.\u003c\/p\u003e\n\u003cp\u003eIP income offers high margins-royalty rates typically 4-12%-and could add materially to revenue given Buchang's 2024 R\u0026amp;D spend of CNY 1.2 billion (≈USD 170m).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing to capture royalties, 4-12% typical\u003c\/li\u003e\n\u003cli\u003eAvoids market-entry cost, leverages CNY 1.2B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003eTargets fast-growing international demand; China deals +18% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExport and International Market Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang is accelerating exports into Southeast Asia and other markets with rising demand for traditional medicine; management targets a 25% CAGR in international revenue from 2024-2027 as approvals expand.\u003c\/p\u003e\n\u003cp\u003eExport growth hinges on securing regulatory clearances and distribution deals; exports made up about 12% of revenue in 2024, with a goal to reach ~30% by 2027 as global partnerships scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 exports = ~12% of revenue\u003c\/li\u003e\n\u003cli\u003eTarget 2027 exports ≈ 30% of revenue\u003c\/li\u003e\n\u003cli\u003eProjected international revenue CAGR 2024-2027 = 25%\u003c\/li\u003e\n\u003cli\u003eFocus regions: Southeast Asia + markets with rising traditional-medicine demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNaoxintong-driven TCM: 65% sales, 38% GM; exports set to hit 30% by 2027\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: prescription TCM (Naoxintong) ~65% of sales in 2024; gross margin ~38% and large repeat base (280M adults with CVD). Secondary: gynecology\/urology ~CNY1.2B (18% of revenue, FY2024). OTC TCM ~28% (CNY1.2B). Licensing royalties 4-12% on R\u0026amp;D CNY1.2B. Exports 12% (2024), target ~30% by 2027 (25% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNotes\/Targets\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription TCM\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003ctd\u003eNaoxintong; gross margin ~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGyne\/Uro\u003c\/td\u003e\n\u003ctd\u003eCNY1.2B (18%)\u003c\/td\u003e\n\u003ctd\u003eNiche therapies, +3pp share 2022-24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC TCM\u003c\/td\u003e\n\u003ctd\u003e~28% (CNY1.2B)\u003c\/td\u003e\n\u003ctd\u003eRetail + online\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/IP\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eRoyalties 4-12%; R\u0026amp;D CNY1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003ctd\u003eTarget ~30% by 2027 (25% CAGR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357473251659,"sku":"buchang-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/buchang-canvas-business-model.webp?v=1779128168","url":"https:\/\/valuechainanalysis.com\/products\/buchang-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}